Patrick Burnett sold $49k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 3,773 shares at an average of $13.10, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +15RoleOfficer
- +7Trade size$49k at market
- 0Share of holdings soldSold 2.2% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001787306-25-000043, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | AGrant or award Common Stock10b5-1 | +38,000 | $0.00 | $0 | 152,862 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Common Stock10b5-1 | +17,000 | $0.00 | $0 | 169,862 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,819 | $13.03 | $37k | 167,043 | Mar 4, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -954 | $13.28 | $13k | 166,089 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +99,000 | $0.00 | $0 | 99,000 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +43,000 | $0.00 | $0 | 43,000 | Mar 4, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 28Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $257k 10,000 shares | -17% | |
| 40Moderate | Arcutis Biotherapeutics, Inc. | Keith R Leonard director | $997k 39,272 shares | -64% | |
| 21Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $158k 6,287 shares | -5% | |
| 25Weak | Arcutis Biotherapeutics, Inc. | Latha Vairavan SVP Chief Financial Officer | $72k 2,853 shares | -3% | |
| 24Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $314k 12,058 shares | -8% | |
| 34Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $941k 37,349 shares | -5% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $93k 3,687 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.